Anti-prolactin receptor antibody formulations

Abstract

Provided are a wide concentration range, especially high concentration, substantially salt-free anti-prolactin receptor antibody formulations that are substantially isosmotic and of low viscosity.

1 - 36 . (canceled) 
     
     
         37 . A method for the non-hormonal treatment of endometriosis in a patient, comprising administering to said patient a therapeutically effective amount of an anti-PRLR antibody formulation 10 mM to 70 mM histidine; 50 ppm to 300 ppm of a non-ionic surfactant; 34 mM to 292 mM of a sugar selected from mannitol, dextrose, glucose, trehalose, and sucrose; 20 mM to 50 mM arginine; 0 mM to 50 mM lysine; 0 mM to 270 mM glycine or alanine; 5 mM to 10 mM methionine; and 1 mg/ml to 150 mg/ml of an anti-PRLR antibody; wherein said anti-PRLR antibody formulation has a pH ranging from pH 5.0 to pH. 
     
     
         38 . The method of  claim 37 , wherein said anti-PRLR antibody formulation is administered intravenously, subcutaneously, or intramuscularly. 
     
     
         39 . The method of  claim 37 , wherein said anti-PRLR antibody comprises a human IgG2 monoclonal antibody. 
     
     
         40 . The method of  claim 39 , wherein said human IgG2 monoclonal antibody comprises a light chain sequence of SEQ ID NO: 1 and a heavy chain sequence of SEQ ID NO: 7.